IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 7.2
(-1.1%)
SEK 7.2
(-1.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 177.12 Million SEK | -45.26% |
| 2022 | 323.55 Million SEK | -31.52% |
| 2021 | 472.44 Million SEK | 27.67% |
| 2020 | 370.06 Million SEK | 77.86% |
| 2019 | 208.06 Million SEK | -7.5% |
| 2018 | 224.93 Million SEK | 38.02% |
| 2017 | 162.97 Million SEK | 44.08% |
| 2016 | 113.11 Million SEK | 11.89% |
| 2015 | 101.09 Million SEK | -5.01% |
| 2014 | 106.42 Million SEK | 325.73% |
| 2013 | 24.99 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 136.66 Million SEK | -22.84% |
| 2024 Q2 | 214.61 Million SEK | 57.03% |
| 2024 Q3 | 160.29 Million SEK | -25.31% |
| 2023 Q3 | 186.91 Million SEK | -18.73% |
| 2023 Q2 | 229.98 Million SEK | -17.11% |
| 2023 Q4 | 177.12 Million SEK | -5.24% |
| 2023 Q1 | 277.45 Million SEK | -14.25% |
| 2023 FY | 177.12 Million SEK | -45.26% |
| 2022 Q1 | 434.85 Million SEK | -7.96% |
| 2022 Q3 | 368.77 Million SEK | -6.88% |
| 2022 FY | 323.55 Million SEK | -31.52% |
| 2022 Q4 | 323.55 Million SEK | -12.26% |
| 2022 Q2 | 396 Million SEK | -8.93% |
| 2021 Q3 | 498.39 Million SEK | 52.36% |
| 2021 FY | 472.44 Million SEK | 27.67% |
| 2021 Q1 | 352.29 Million SEK | -4.8% |
| 2021 Q4 | 472.44 Million SEK | -5.21% |
| 2021 Q2 | 327.11 Million SEK | -7.15% |
| 2020 Q2 | 296.33 Million SEK | -6.07% |
| 2020 FY | 370.06 Million SEK | 77.86% |
| 2020 Q4 | 370.06 Million SEK | 39.73% |
| 2020 Q3 | 264.84 Million SEK | -10.63% |
| 2020 Q1 | 315.49 Million SEK | 51.63% |
| 2019 FY | 208.06 Million SEK | -7.5% |
| 2019 Q2 | 189.06 Million SEK | -10.87% |
| 2019 Q4 | 208.06 Million SEK | 26.63% |
| 2019 Q3 | 164.31 Million SEK | -13.09% |
| 2019 Q1 | 212.11 Million SEK | -5.7% |
| 2018 Q2 | 263.85 Million SEK | 75.71% |
| 2018 FY | 224.93 Million SEK | 38.02% |
| 2018 Q3 | 241.79 Million SEK | -8.36% |
| 2018 Q1 | 150.16 Million SEK | -7.86% |
| 2018 Q4 | 224.93 Million SEK | -6.97% |
| 2017 FY | 162.97 Million SEK | 44.08% |
| 2017 Q1 | 208.02 Million SEK | 83.91% |
| 2017 Q2 | 193.74 Million SEK | -6.87% |
| 2017 Q3 | 184.68 Million SEK | -4.68% |
| 2017 Q4 | 162.97 Million SEK | -11.75% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | 113.11 Million SEK | 11.89% |
| 2016 Q4 | 113.11 Million SEK | 0.0% |
| 2015 FY | 101.09 Million SEK | -5.01% |
| 2014 FY | 106.42 Million SEK | 325.73% |
| 2013 FY | 24.99 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | -43.78% |
| Amniotics AB (publ) | 26.08 Million SEK | -578.989% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -2814.612% |
| BioArctic AB (publ) | 1.18 Billion SEK | 85.067% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 90.681% |
| Saniona AB (publ) | 64.14 Million SEK | -176.135% |
| Simris Alg AB (publ) | 174.55 Million SEK | -1.472% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 64.308% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -1091.21% |
| NextCell Pharma AB | 81.28 Million SEK | -117.893% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -487.018% |
| AcouSort AB (publ) | 34.51 Million SEK | -413.201% |
| Active Biotech AB (publ) | 44 Million SEK | -302.548% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -49.532% |
| Camurus AB (publ) | 1.9 Billion SEK | 90.716% |
| Cantargia AB (publ) | 223.71 Million SEK | 20.826% |
| Genovis AB (publ.) | 288.85 Million SEK | 38.682% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -107.823% |
| Mendus AB (publ) | 755.95 Million SEK | 76.57% |
| Kancera AB (publ) | 65.64 Million SEK | -169.825% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 85.925% |
| LIDDS AB (publ) | 17.65 Million SEK | -903.234% |
| Lipum AB (publ) | 12.11 Million SEK | -1362.601% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -427.114% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 36.458% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -783.793% |
| OncoZenge AB (publ) | 20.34 Million SEK | -770.801% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 72.897% |
| Xintela AB (publ) | 18.39 Million SEK | -862.876% |
| Ziccum AB (publ) | 14.97 Million SEK | -1083.015% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -25.978% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 76.855% |
| CombiGene AB (publ) | 120.61 Million SEK | -46.852% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 18.392% |
| Intervacc AB (publ) | 259.61 Million SEK | 31.774% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -183.952% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -322.129% |
| Corline Biomedical AB | 100.1 Million SEK | -76.935% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -184.98% |
| Aptahem AB (publ) | 63.02 Million SEK | -181.033% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 49.586% |
| Fluicell AB (publ) | 9.34 Million SEK | -1796.37% |
| Biovica International AB (publ) | 131.4 Million SEK | -34.787% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -234.285% |
| Abliva AB (publ) | 87.49 Million SEK | -102.426% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 76.701% |
| 2cureX AB (publ) | 16.62 Million SEK | -965.389% |
| I-Tech AB | 152.44 Million SEK | -16.188% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 82.602% |
| Cyxone AB (publ) | 43.65 Million SEK | -305.729% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -125.081% |
| Biosergen AB | 7.2 Million SEK | -2359.672% |
| Nanologica AB (publ) | 77.42 Million SEK | -128.753% |
| SynAct Pharma AB | 228.01 Million SEK | 22.322% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -561.813% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 87.35% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -716.118% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 25.697% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -1994.867% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -103.419% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -521.303% |